U.S. markets closed

CAE Inc. (CAE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
17.07+0.04 (+0.23%)
At close: 4:00PM EDT

17.07 0.00 (0.00%)
After hours: 4:15PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close17.03
Open17.05
Bid17.03 x 900
Ask17.05 x 800
Day's Range17.00 - 17.36
52 Week Range9.80 - 31.56
Volume493,847
Avg. Volume401,784
Market Cap4.537B
Beta (5Y Monthly)1.94
PE Ratio (TTM)17.07
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 12, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-23% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Media Advisory: CAE's FY2021 second quarter financial results and conference call
    PR Newswire

    Media Advisory: CAE's FY2021 second quarter financial results and conference call

    (NYSE: CAE) (TSX: CAE) – CAE will release its fiscal year 2021 second quarter results on Tuesday, November 10, 2020. A conference call will be held on the same day at 1 p.m. Eastern Time (ET) to provide analysts and institutional investors with a review of CAE's performance and outlook.

  • Health Canada has approved TALTZ® (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA)
    CNW Group

    Health Canada has approved TALTZ® (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA)

    TALTZ is now approved to treat patients across the axSpA spectrum, including ankylosing spondylitis and non-radiographic axSpA TORONTO, Oct. 19, 2020 /CNW/ - On October 14, 2020, Health Canada approved TALTZ® for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have responded inadequately to, or are intolerant to conventional therapy.

  • CAE becomes first Canadian aerospace company to become carbon neutral
    PR Newswire

    CAE becomes first Canadian aerospace company to become carbon neutral

    (NYSE: CAE) (TSX: CAE) – CAE today announced that it has become carbon neutral as of September 28, 2020, proudly becoming the first Canadian aerospace company to reach this goal. The company has achieved carbon neutrality by continuing to reduce its own emissions and by making investments in projects that offset its remaining annual carbon emissions.